HealthTree Logo
search more_vert
close
person Sign In / Create Account
The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed?
The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed? image
Relapsed/Refractory Myeloma
event May 22, 2024 / 01:00PM - 02:00PM EDT
videocam
Can't make it to the event?
We send a recording to all registered participants of the event!

Event Description

Maintenance therapy remains standard for most myeloma patients in today's treatment landscape. How has that changed throughout myeloma treatment history and what could the future of maintenance therapy look like? We look forward to hearing Dr. Sam Rubinstein's thoughts on the subject.

Schedule & Agenda

The panelist Marisol Garcia
Introductions
1:00 PM
Marisol Garcia

Marisol introduces the agenda of the event and featured speaker Dr. Sam Rubinstein.

The panelist Dr. Samuel Rubinstein
Presentation
1:05 PM
Dr. Samuel Rubinstein

Dr. Sam Rubinstein shares his thoughts on maintenance therapy.

 

person
Questions and Answers
1:35 PM
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Marisol Garcia
Marisol Garcia

Soy la Coordinadora de Eventos en la fundación de HealthTree. En conjunto con la Directora de Eventos trabajamos para traer reuniones de diferentes temas de interés para los pacientes. Nuestra misión es hacer llegar nuestro programa a más gente, tanto en inglés como en español.

Read Bio
The panelist Dr. Samuel Rubinstein
Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life with Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Abbvie
Astellas Pharma
Servier

Follow Us

facebook instagram youtube